Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease vascular disease
Symptom |diabetes
Sentences 526
PubMedID- 26180307 Theage-adjusted incidence of hypertension and coronary heart disease was 38% and 24%,respectively, showing a clear incidence of diabetes associated with cardiovascular diseasein saudi arabia.
PubMedID- 24567354 Increased white blood cell (wbc) count is related to cardiovascular disease in patients with type 2 diabetes mellitus; raised neutrophil lymphocyte ratio (nlr) is associated with metabolic syndrome.
PubMedID- 24396666 Other recent reports showed that variations in long-term glycemia, defined as a1c variability, were powerful independent predictors for diabetic microvascular complications and even for cardiovascular disease (cvd) events in patients with type 1 diabetes .
PubMedID- 20591087 diabetes leads to premature cardiovascular disease and is regarded by many as the most common etiological factor for chronic kidney disease.
PubMedID- 25328404 Aim/introduction: circulating levels of n-terminal fragment of probrain natriuretic peptide (nt-probnp) are established as a risk factor for cardiovascular disease and mortality in patients with diabetes, as well as in the general population.
PubMedID- 22526620 Poorly managed type 1 diabetes can lead to cardiovascular disease, diabetic neuropathy, and diabetic retinopathy.
PubMedID- 23730303 Abnormal endothelial function is a salient feature of vascular disease in diabetes that is exemplified by a decrease in nitric oxide (no) synthesis or bioavailability.
PubMedID- 25923078 Type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls.
PubMedID- 25527522 Conclusions: in our series, type 2 diabetes mellitus patients with cardiovascular disease at baseline present with an increased risk of developing diabetic peripheral neuropathy at 10 years of follow-up.
PubMedID- 22373102 Percutaneous therapy for limb-threatening lower extremity vascular disease with or without diabetes has no exception, with primary patency rates at 36 months of 46.5% and 60.9%.
PubMedID- 22496883 This study provides new targets for drug development and new strategies for the prevention and treatment of vascular diseases in diabetes patients with hypertension.
PubMedID- PMC4484638 Even though the exact mechanism for accelerated vascular disease in diabetes is not yet fully clear, existing research has defined numerous risk factors involved in diabetes, such as oxidative stress , dyslipidemia , advanced glycation .
PubMedID- 21035578 There is also strong evidence that blood pressure targets for populations at high risk of cardiovascular disease, including those with diabetes, coronary artery disease, and chronic kidney disease, should be lower than 140/90 mm hg.
PubMedID- 24905298 General significance: this strategy might prove clinically relevant in preventing the development and/or retarding the progression of diabetes associated with vascular diseases.
PubMedID- 21109113 Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the advance (action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation) trial.
PubMedID- 22474525 A therapeutic effect of myricetin in patients with cardiovascular diseases associated with diabetes mellitus has also been reported .
PubMedID- 24462067 Results of epidemiologic studies that investigated the significance of pulse pressure (pp) and mean arterial pressure (map) in terms of risk of cardiovascular disease (cvd) in patients with diabetes mellitus are inconsistent.
PubMedID- 26100640 Nobody disputes the fact that type 1 diabetes increases the risk of death from cardiovascular diseases.
PubMedID- 23166795 Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease.
PubMedID- 23275938 proposed that the cut-off point for the bapwv in type 2 diabetes patients with cardiovascular disease was 1,635 cm/sec (sensitivity 73%, specificity 75%).
PubMedID- 21926285 diabetes is associated with microvascular disease, white matter hyperintensities (wmhs), cerebral atrophy (1,2), and functional decline (3,4).
PubMedID- 22530043 Furthermore, in that study, lvm regression was independently associated with improved patient survival even after adjustment for age, gender, diabetes, history of cardiovascular disease, and all nonspecific cardiovascular risk factors.
PubMedID- 26199685 Background: diabetes is associated with increased cardiovascular disease, mortality and morbidity.
PubMedID- 20350283 Despite the profound clinical importance of vascular disease in patients with diabetes mellitus, our understanding of the molecular and cellular mechanisms by which diabetes promotes these vascular complications is incomplete.
PubMedID- 25325279 Many studies have reported postprandial hyperglycemia as a major cause of adverse cardiovascular disease in patients with diabetes mellitus .
PubMedID- 25899686 Cirrhosis) is higher than that for cardiovascular disease among patients with diabetes .
PubMedID- 23082138 Model ii: adjustment for the covariates mentioned above plus diabetes, history of hypertension, previous cardiovascular disease, and medication treatment.
PubMedID- 23878823 Atherosclerosis that is often found in type 2 diabetes is a complication of macrovascular disease that increases the risk for myocardial infarction and strokes.
PubMedID- 19232762 Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
PubMedID- 20601395 Methods and results: one hundred and fifty type 2 diabetes patients with cardiovascular disease (cvd) or >/= 1 other cvd risk factor were randomized to receive rosiglitazone vs.
PubMedID- 20185811 The present study includes 740 men and 777 women with diabetes who were free of cancer and cardiovascular disease at blood draw, and who had detectable lp-pla2 activity values.
PubMedID- 26313785 A study by tobias et al20 reported results similar to ours with a j-shaped association across bmi categories for all-cause mortality in participants with incident diabetes who were free of cardiovascular disease and cancer at the time of a diagnosis of diabetes.
PubMedID- 25227555 Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in spain: percedime2 study.
PubMedID- 23144257 Hypertension and diabetes are initial stages of cardiovascular disease, and the risk is elevated because of the high prevalence of tobacco smoking among men.
PubMedID- 24505486 Further confining the analysis to participants with complete data for bmi, waist circumference, blood pressure, smoking status, diabetes status, history of cardiovascular disease, poverty:income ratio and time of day of venepuncture gave a total of n = 19,381 included in the analyses of serum phosphorus, total alp and estimated dietary phosphorus intake.
PubMedID- 22994452 Regarding cardiovascular mortality, age, diabetes mellitus, history of cardiovascular disease, lvmi, lvef, cimt, and pwv were significant predictors (table2).
PubMedID- 26381503 Erythropoiesis stimulating agent (esa) treatments targeting mild anemia (10-12 g/dl) can decrease the risk of occurrence of cardiovascular disease (cvd) in patients with hypertension, diabetes mellitus and congestive heart failure.
PubMedID- 23940992 Study included 313 normoalbuminuric patients with type 1 diabetes, none showed signs of adrenal, renal, or cardiovascular diseases.
PubMedID- 24498934 Ev-markers and the risk of new onset type 2 diabetes in patients with manifest cardiovascular disease.
PubMedID- 23844096 The correlations between tat and patency remained significant after adjustment for age, diabetes, smoking, history of cardiovascular disease, and number of days since avf creation in a multivariate linear regression model.
PubMedID- 21468921 To confirm the efficacy of metformin use on triglyceride level and hdl-c level associated with the risk of cardiovascular disease in patient with diabetes, further placebo-controlled investigations are required.
PubMedID- 20967275 For example, chronic hypertension is primarily characterized by endothelial dysfunction and microvascular disease whereas with diabetes the pathology may be due to direct effects of hyperglycemia in addition to vascular disease.
PubMedID- 24616778 (6) attempted to demonstrate direct causation by examining cardiac innervation using metaiodobenzylguanidine imaging in patients with diabetes and no history of cardiovascular disease.
PubMedID- 21080957 Therefore, based on the findings from the present study and the accumulating body of clinical evidence with exenatide, therapy with glp-1 receptor agonists may represent a promising approach for the treatment of patients with chf or cardiovascular disease associated with type 2 diabetes, supporting the need for further research in this field.
PubMedID- 25790898 Cardiovascular disease among women with and without diabetes mellitus and bilateral oophorectomy.
PubMedID- 23738538 Among people with diabetes, the highest risk of death from cardiovascular disease is found in those treated with oral hypoglycemic drugs or insulin and in those with longer duration of diabetes .
PubMedID- 22701470 Functional abnormalities of the vascular endothelial lining have been shown to precede overt cardiovascular disease in patients with and without diabetes .
PubMedID- 24651718 Glp-1 receptor agonist represents a novel approach for the treatment of patients with cardiovascular disease associated with type 2 diabetes .
PubMedID- 21735134 We prospectively studied 2,277 cardiac patients, and the results show high congruence between the markov model and the ph model; both evidence that diabetes, history of stroke, peripheral vascular disease and smoking significantly increase hazard rate and reduce survival time.
PubMedID- 22234950 Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.

Page: 1 2 3 4 5 6 7 8 9 10 11